Cargando…
A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma
SIMPLE SUMMARY: Uveal melanoma is a rare subset of melanoma characterized by the presence of early initiating GNAQ/11 mutations, with downstream activation of several pathways which are thought to contribute to cell growth. Based on clinical and preclinical data supporting targeting of protein kinas...
Autores principales: | Shoushtari, Alexander N., Khan, Shaheer, Komatsubara, Kimberly, Feun, Lynn, Acquavella, Nicolas, Singh-Kandah, Shahnaz, Negri, Tiffany, Nesson, Alexandra, Abbate, Kelly, Cremers, Serge, Musi, Elgilda, Ambrosini, Grazia, Lee, Shing, Schwartz, Gary K., Carvajal, Richard D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583628/ https://www.ncbi.nlm.nih.gov/pubmed/34771668 http://dx.doi.org/10.3390/cancers13215504 |
Ejemplares similares
-
A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma
por: Bauer, Sebastian, et al.
Publicado: (2023) -
Intermittent MEK inhibition for the treatment of metastatic uveal melanoma
por: Khan, Shaheer, et al.
Publicado: (2022) -
Sotrastaurin, a PKC inhibitor, attenuates RANKL‐induced bone resorption and attenuates osteochondral pathologies associated with the development of OA
por: Pang, Cong, et al.
Publicado: (2020) -
BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells
por: Ambrosini, Grazia, et al.
Publicado: (2015) -
The GPER Agonist LNS8801 Induces Mitotic Arrest and Apoptosis in Uveal Melanoma Cells
por: Ambrosini, Grazia, et al.
Publicado: (2023)